Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 574

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

Open access
Roila, F., Molassiotis, A., Herrstedt, J., Aapro, M., Gralla, R.J., Bruera, E., Clark-Snow, R.A., Dupuis, L.L., Einhorn, L.H., Feyer, P., Hesketh, P.J., Jordan, K., Olver, I., Rapoport, B.L., Roscoe, J., Ruhlmann, C.H., Walsh, D., Warr, D., van der Wetering, M.·2016·Annals of Oncology
DOI 10.1093/annonc/mdw270
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdw270

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 27

  1. Grunberg, 2005, Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update, Support Care Cancer, 13, 80, 10.1007/s00520-004-0718-y · doi:10.1007/s00520-004-0718-y
  2. Saito, 2013, Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial, Ann Oncol, 24, 1067, 10.1093/annonc/mds541 · doi:10.1093/annonc/mds541
  3. Rapoport, 2015, Study of rolapitant, a novel, long-acting, NK1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC), Support Care Cancer, 23, 3281, 10.1007/s00520-015-2738-1 · doi:10.1007/s00520-015-2738-1
  4. Roila, 2015, Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study, Ann Oncol, 26, 1248, 10.1093/annonc/mdv132 · doi:10.1093/annonc/mdv132
  5. Saito, 2009, Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial, Lancet Oncol, 10, 115, 10.1016/S1470-2045(08)70313-9 · doi:10.1016/s1470-2045(08)70313-9
  6. Brygger, 2014, 5-hydroxytryptamine3 receptor antagonists and cardiac side effects, Expert Opin Drug Saf, 13, 1407, 10.1517/14740338.2014.954546 · doi:10.1517/14740338.2014.954546
  7. Karthaus, 2015, Support Care Cancer, 23, 2917, 10.1007/s00520-015-2657-1 · doi:10.1007/s00520-015-2657-1
  8. Boccia, 2013, Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial, Support Care Cancer, 21, 1453, 10.1007/s00520-012-1691-5 · doi:10.1007/s00520-012-1691-5
  9. Popovic, 2014, Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials, Support Care Cancer, 22, 1685, 10.1007/s00520-014-2175-6 · doi:10.1007/s00520-014-2175-6
  10. Weinstein, 2016, Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial, Ann Oncol, 27, 172, 10.1093/annonc/mdv482 · doi:10.1093/annonc/mdv482
  11. Hesketh, 2016, Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy, Cancer, 122, 2418, 10.1002/cncr.30054 · doi:10.1002/cncr.30054
  12. Tanioka, 2013, A randomized, placebo controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy, Br J Cancer, 109, 859, 10.1038/bjc.2013.400 · doi:10.1038/bjc.2013.400
  13. Yahata, 2016, Int J Clin Oncol, 21, 491, 10.1007/s10147-015-0928-y · doi:10.1007/s10147-015-0928-y
  14. Nishimura, 2015, Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial, Eur J Cancer, 51, 1274, 10.1016/j.ejca.2015.03.024 · doi:10.1016/j.ejca.2015.03.024
  15. Olver, 2013, Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in a 5-day cisplatin-based germ cell tumor chemotherapy, Support Care Cancer, 21, 1561, 10.1007/s00520-012-1696-0 · doi:10.1007/s00520-012-1696-0
  16. Hamada, 2014, Antiemetic efficacy and safety of a combination of palonosetron, aprepitant and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy, Support Care Cancer, 22, 2161, 10.1007/s00520-014-2182-7 · doi:10.1007/s00520-014-2182-7
  17. Keat, 2013, Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low-emetogenic chemotherapy?, Asian Pac J Cancer Prev, 14, 469, 10.7314/APJCP.2013.14.1.469 · doi:10.7314/apjcp.2013.14.1.469
  18. Chanthawong, 2014, Effective of olanzapine for the treatment of breakthrough chemotherapy-induced nausea and vomiting, J Med Assoc Thai, 97, 349
  19. Sigsgaard, 2001, Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy, J Clin Oncol, 19, 2091, 10.1200/JCO.2001.19.7.2091 · doi:10.1200/jco.2001.19.7.2091
  20. Pielichowski, 2011, A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation, Transplant Proc, 43, 3107, 10.1016/j.transproceed.2011.08.010 · doi:10.1016/j.transproceed.2011.08.010
  21. Bechtel, 2014, Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study, Support Care Cancer, 22, 2911, 10.1007/s00520-014-2248-6 · doi:10.1007/s00520-014-2248-6
  22. Stiff, 2013, Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens, Biol Blood Marrow Transplant, 19, 49, 10.1016/j.bbmt.2012.07.019 · doi:10.1016/j.bbmt.2012.07.019
  23. Maranzano, 2010, A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres, Radiother Oncol, 94, 36, 10.1016/j.radonc.2009.11.001 · doi:10.1016/j.radonc.2009.11.001
  24. Dennis, 2013, Timing and duration of 5-HT3 receptor antagonist therapy for the prophylaxis of radiotherapy-induced nausea and vomiting: a systematic review of randomized and non-randomized studies, J Radiat Oncol, 2, 271, 10.1007/s13566-012-0030-2 · doi:10.1007/s13566-012-0030-2
  25. Bakhshi, 2015, Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial, Support Care Cancer, 23, 3229, 10.1007/s00520-015-2714-9 · doi:10.1007/s00520-015-2714-9
  26. Kang, 2015, Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial, Lancet Oncol, 16, 385, 10.1016/S1470-2045(15)70061-6 · doi:10.1016/s1470-2045(15)70061-6
  27. Laval, 2012, SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction, Bull Cancer, 99, E1, 10.1684/bdc.2011.1535 · doi:10.1684/bdc.2011.1535

Cited by

See all 574

Metadata

Authors
Roila, F., Molassiotis, A., Herrstedt, J., Aapro, M., Gralla, R. J., Bruera, E., Clark-Snow, R. A., Dupuis, L. L., Einhorn, L. H., Feyer, P., Hesketh, P. J., Jordan, K., Olver, I., Rapoport, B. L., Roscoe, J., Ruhlmann, C. H., Walsh, D., Warr, D., & van der Wetering, M.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2016-09
Volume
27
Issue
suppl 5
Pages
v119-v133
ISSN
0923-7534 (ISSN-L)
DOI
10.1093/annonc/mdw270
OpenAlex
W2527377692
Cited by
574
References
41
FWCI
62.73
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • MASCC
  • ESMO

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. https://app.cochat.ai/papers/10.1093/annonc/mdw270
The paper
Roila, F., Molassiotis, A., Herrstedt, J., Aapro, M., Gralla, R. J., Bruera, E., Clark-Snow, R. A., Dupuis, L. L., Einhorn, L. H., Feyer, P., Hesketh, P. J., Jordan, K., Olver, I., Rapoport, B. L., Roscoe, J., Ruhlmann, C. H., Walsh, D., Warr, D., & van der Wetering, M. (2016). 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Annals of Oncology. https://doi.org/10.1093/annonc/mdw270

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.